• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 3 - Pairing Patients with the Right Therapies

Article

In this clip, Kimberly Shafer-Weaver, PhD, discusses specific biomarkers that could establish utilities for specific patient populations and measuring response to drugs.

In this clip, Kimberly Shafer-Weaver, PhD, discusses specific biomarkers that could establish utilities for specific patient populations and measuring response to drugs.

Dr Shafer-Weaver explains that with CTLA-4, melanoma responds well to immunotherapy, but there is work being done currently regarding PD-1 and PD-L1. Results show that even though PD-L1 negative tumor respond well, patients highly express PD-L1 respond better.

“I think the biggest thing right now is there is no consistency in the field, and so I think it is kind of hard right now at this stage to get a grasp on that because we do not have standardized assays that all labs do the same,” she said. “It is not a common thing; specialized labs do that.”

Related Videos
CK Wang, MD, COTA
Eric Lander, MD
Eric Lander, MD
David Awad, PharmD, BCOP
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.